The Phase II clinical trial will test the efficacy of psilocybin on treatment resistant Post Traumatic Stress Disorder (PTSD).
Field Trip has now completed the dosing of the first patients in its Phase 1 clinical study: A double-blind, randomised, placebo-controlled study to investigate the safety,...
Origin Therapeutics has completed an investment in Clairvoyant Therapeutics which will now proceed with a Phase 2 clinical trial for the clinical validation of psilocybin for the treatment of alcohol use...
Clinilabs Drug Development Corporation has begun enrolment in a Phase 1/2a clinical trial of Cybin’s CYB003 for the treatment of major depressive disorder (MDD).
Algernon Pharmaceuticals is working to complete an intravenous formulation (IVF) that will be used in its Phase 1 DMT study investigating the compound’s efficacy as a...
Filament Health has confirmed it has begun dosing in the first FDA-approved clinical trial studying the effects of naturally derived psychedelic drug candidates.
A novel compound similar in structure to the psychedelic drug ibogaine, but which has no hallucinogenic effects, has been found to rapidly reverse the effects of...
The UK’s national innovation agency – Innovate UK – has provided funding to Awakn Life Sciences to help bring its ketamine-assisted therapy to alcohol use disorder...
Results from the largest longitudinal study investigating the practice of microdosing psilocybin for mental health, and one of the few to use a control group, have...
Cybin has confirmed that it has received a “may proceed letter” and Investigational New Drug Application (IND) clearance from the U.S.